Movement Disorders (revue)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Dyskinésie And NotJ. Vaamonde

List of bibliographic references

Number of relevant bibliographic references: 281.
Ident.Authors (with country if any)Title
000048 Manuel Alegre [Espagne] ; Jon Lopez-Azcarate [Espagne] ; Fernando Alonso-Frech [Espagne] ; Maria C. Rodriguez-Oroz [Espagne] ; Miguel Valencia [Espagne] ; Jorge Guridi [Espagne] ; Julio Artieda [Espagne] ; Jose A. Obeso [Espagne]Subthalamic Activity During Diphasic Dyskinesias in Parkinson's Disease
000088 Stewart A. Factor [États-Unis]Propranolol Therapy for Tardive Dyskinesia Revisited
000095 Antonio Cerasa [Italie] ; Pierfrancesco Pugliese [Italie] ; Demetrio Messina [Italie] ; Maurizio Morelli [Italie] ; Maria Cecilia Gioia [Italie] ; Maria Salsone [Italie] ; Fabiana Novellino [Italie] ; Giuseppe Nicoletti [Italie] ; Gennarina Arabia [Italie] ; Aldo Quattrone [Italie]Prefrontal Alterations in Parkinson's Disease with Levodopa-Induced Dyskinesia During fMRI Motor Task
000104 Selma Aybek [Suisse] ; Andrea O. Rossetti [Suisse] ; Malin Maeder-Ingvar [Suisse] ; François J. G. Vingerhoets [Suisse]Paroxysmal Kinesigenic Dyskinesias of Epileptic Origin Abolished by Temporal Lobectomy
000148 Thomas Mathew [Inde] ; Sushanth Aroor [Inde] ; Raghunandan Nadig [Inde] ; G. R. K. Sarma [Inde]Lacosamide in Paroxysmal Kinesigenic Dyskinesia
000251 Lonneke M. L. De Lau [Pays-Bas] ; Dagmar Verbaan [Pays-Bas] ; Johan Marinus [Pays-Bas] ; Peter Heutink [Pays-Bas] ; Jacobus J. Van Hilten [Pays-Bas]Catechol-O-methyltransferase Val158Met and the Risk of Dyskinesias in Parkinson's Disease
000310 Susan H. Fox [Canada] ; Tom H. Johnston [Canada] ; QIN LI [République populaire de Chine] ; Jonathan Brotchie [Canada] ; Erwan Bezard [République populaire de Chine, France]A Critique of Available Scales and Presentation of the Non-Human Primate Dyskinesia Rating Scale
000314 Florence C. F. Chang [Australie] ; Prachi Mehta [Australie] ; Brianada Koentjoro [Australie] ; Mark Latt [Australie] ; Nick Blair [Australie] ; Garth Nicholson [Australie] ; Carolyn M. Sue [Australie] ; Victor S. C. Fung [Australie]"Dancing Feet Dyskinesias": A Clue to Parkin Gene Mutations
000349 James B. Koprich [Canada] ; Susan H. Fox [Canada] ; Tom H. Johnston [Canada] ; Allan Goodman [États-Unis] ; Bertrand Le Bourdonnec [États-Unis] ; Roland E. Dolle [États-Unis] ; Robert N. Dehaven [États-Unis] ; Diane L. Dehaven-Hudkins [États-Unis] ; Patrick J. Little [États-Unis] ; Jonathan M. Brotchie [Canada]The Selective Mu-Opioid Receptor Antagonist ADL5510 Reduces Levodopa-Induced Dyskinesia Without Affecting Antiparkinsonian Action in MPTP-Lesioned Macaque Model of Parkinson's Disease
000378 Christopher G. Goetz [États-Unis] ; Glenn T. Stebbins [États-Unis] ; Ad Theeuwes [Pays-Bas] ; Fabrizio Stocchi [Italie] ; Joaquim J. Ferreira [Portugal] ; Serge Van De Witte [Pays-Bas] ; Juliana Bronzova [Pays-Bas]Temporal Stability of the Unified Dyskinesia Rating Scale
000380 Maria Sierra Pena [États-Unis] ; Toby C. Yaltho [États-Unis] ; Joseph Jankovic [États-Unis]Tardive Dyskinesia and Other Movement Disorders Secondary to Aripiprazole
000383 Christopher Kobylecki [Royaume-Uni] ; Michael P. Hill [Canada] ; Alan R. Crossman [Royaume-Uni] ; Paula Ravenscroft [Royaume-Uni, Canada]Synergistic Antidyskinetic Effects of Topiramate and Amantadine in Animal Models of Parkinson's Disease
000459 Kailash P. Bhatia [Royaume-Uni]Paroxysmal Dyskinesias
000460 Mohan Madhusudanan [Inde] ; Kailash P. Bhatia [Royaume-Uni] ; Bettina Balint [Allemagne]Paroxysmal Craniocervical Dyskinesia as Manifestation of Frontal Lobe Epilepsy
000494 Shinji Ono [Japon] ; Koh-Ichiro Yoshiura [Japon] ; Naohiro Kurotaki [Japon] ; Taeko Kikuchi [Japon] ; Norio Niikawa [Japon] ; Akira Kinoshita [Japon]Mutation and Copy Number Analysis in Paroxysmal Kinesigenic Dyskinesia Families
000510 Thomas Wichmann [États-Unis] ; Mahlon R. Delong [États-Unis] ; Jorge Guridi [Espagne] ; Jose A. Obeso [Espagne]Milestones in Research on the Pathophysiology of Parkinson's Disease
000542 Jasper E. Visser [Pays-Bas] ; David J. Schretlen [États-Unis] ; Bastiaan R. Bloem [Pays-Bas] ; Hyder A. Jinnah [États-Unis]Levodopa is Not a Useful Treatment for Lesch-Nyhan Disease
000544 P. Stathis [Grèce] ; S. Konitsiotis [Grèce] ; G. Tagaris [Grèce] ; D. Peterson [Finlande]Levetiracetam for the Management of Levodopa-Induced Dyskinesias in Parkinson's Disease
000564 Antonio Cerasa [Italie] ; Demetrio Messina [Italie] ; Pierfrancesco Pugliese [Italie] ; Maurizio Morelli [Italie] ; Pierluigi Lanza [Italie] ; Maria Salsone [Italie] ; Fabiana Novellino [Italie] ; Giuseppe Nicoletti [Italie] ; Gennarina Arabia [Italie] ; Aldo Quattrone [Italie]Increased Prefrontal Volume in PD with Levodopa-Induced Dyskinesias: A Voxel-Based Morphometry Study
000587 Marios Politis [Royaume-Uni] ; Wolfgang H. Oertel [Allemagne] ; KIT WU [Royaume-Uni] ; Niall P. Quinn [Royaume-Uni] ; Oliver Pogarell [Allemagne] ; David J. Brooks [Royaume-Uni] ; Anders Bjorklund [Suède] ; Olle Lindvall [Suède] ; Paola Piccini [Royaume-Uni]Graft-Induced Dyskinesias in Parkinson's Disease: High Striatal Serotonin/Dopamine Transporter Ratio
000619 Richard A. Walsh [Canada] ; Anthony E. Lang [Canada]Early-Onset Tardive Dyskinesia in a Neuroleptic-Naive Patient Exposed to Low-Dose Quetiapine
000634 Jee-Young Lee [Corée du Sud] ; Jinwhan Cho [Corée du Sud] ; Eun-Kyung Lee [Corée du Sud] ; Sung-Sup Park [Corée du Sud] ; Beom S. Jeon [Corée du Sud]Differential Genetic Susceptibility in Diphasic and Peak-Dose Dyskinesias in Parkinson's Disease
000689 Alberto J. Espay [États-Unis] ; Jennifer E. Vaughan [États-Unis] ; Rakesh Shukla [États-Unis] ; Maureen Gartner [États-Unis] ; Alok Sahay [États-Unis] ; Fredy J. Revilla [États-Unis] ; Fredy J. Revilla [États-Unis] ; Andrew P. Duker [États-Unis]Botulinum Toxin Type A for Levodopa-Induced Cervical Dyskinesias in Parkinson's Disease: Unfavorable Risk-Benefit Ratio
000729 Daniela Berg [Allemagne] ; Jana Godau [Allemagne] ; Claudia Trenkwalder [Allemagne] ; Karla Eggert [Allemagne] ; Ilona Csoti [Allemagne] ; Alexander Storch [Allemagne] ; Heiko Huber [Allemagne] ; Monica Morelli-Canelo [Allemagne] ; Maria Stamelou [Allemagne] ; Vincent Ries [Allemagne] ; Martin Wolz [Allemagne] ; Christine Schneider [Allemagne] ; Therese Di Paolo [Canada] ; Fabrizio Gasparini [Suisse] ; Sam Hariry [Suisse] ; Marc Vandemeulebroecke [Suisse] ; Walid Abi-Saab [Suisse] ; Katy Cooke [Royaume-Uni] ; Donald Johns [Suisse] ; Baltazar Gomez-Mancilla [Suisse]AFQ056 Treatment of Levodopa-Induced Dyskinesias: Results of 2 Randomized Controlled Trials
000734 Kitty K. Wong [Australie] ; Jane E. Alty [Australie] ; Amanda G. Goy [Australie] ; Sanjay Raghav [Australie] ; David C. Reutens [Australie] ; Peter A. Kempster [Australie]A Randomized, Double-Blind, Placebo-Controlled Trial of Levetiracetam for Dyskinesia in Parkinson's Disease
000748 Evzen Ruzicka [République tchèque] ; Katefina Zarubova [République tchèque] ; John G. Nutt [États-Unis] ; Bastiaan R. Bloem [Pays-Bas]"Silly Walks" in Parkinson's Disease: Unusual Presentation of Dopaminergic-Induced Dyskinesias
000781 Tom H. Johnston [Canada] ; Susan H. Fox [Canada] ; Matthew J. Piggott [Australie] ; Juha-Matti Savola [Suisse] ; Jonathan M. Brotchie [Canada]The α2 Adrenergic Antagonist Fipamezole Improves Quality of Levodopa Action in Parkinsonian Primates
000812 Carlo Colosimo [Italie] ; Pablo Martinez-Martin [Espagne] ; Giovanni Fabbrini [Italie] ; Robert A. Hauser [États-Unis] ; Marcelo Merello [Argentine] ; Janis Miyasaki [Canada] ; Werner Poewe [Autriche] ; Cristina Sampaio [Portugal] ; Olivier Rascol [France] ; Glenn T. Stebbins [États-Unis] ; Anette Schrag [Royaume-Uni] ; Christopher G. Goetz [États-Unis]Task Force Report on Scales to Assess Dyskinesia in Parkinson's Disease: Critique and Recommendations
000849 Karla Eggert [Allemagne] ; David Squillacote [États-Unis] ; Paolo Barone [Italie] ; Richard Dodel [Allemagne] ; Regina Katzenschlager [Autriche] ; Murat Emre [Turquie] ; Andrew Lees (neurologue) [Royaume-Uni] ; Olivier Rascol [France] ; Werner Poewe [Autriche] ; Eduardo Tolosa [Espagne] ; Claudia Trenkwalder [Allemagne] ; Marco Onofrj [Italie] ; Fabrizio Stocchi [Italie] ; Giuseppe Nappi [Italie] ; Vladimir Kostic [Serbie] ; Jagoda Potic [Serbie] ; Evzen Ruzicka [République tchèque] ; Wolfgang Oertel [Allemagne]Safety and Efficacy of Perampanel in Advanced Parkinson's Disease: A Randomized, Placebo-Controlled Study
000851 Manolo Carta [Suède] ; Thomas Carlsson [Suède] ; Ana Munoz [Suède] ; Deniz Kirik [Suède] ; Anders Björklund [Suède]Role of Serotonin Neurons in the Induction of Levodopa- and Graft-Induced Dyskinesias in Parkinson's Disease
000898 Kayhan A. Tayarani-Binazir [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Sarah Rose [Royaume-Uni] ; C. Warren Olanow [États-Unis] ; Peter Jenner [Royaume-Uni]Pramipexole Combined with Levodopa Improves Motor Function but Reduces Dyskinesia in MPTP-Treated Common Marmosets
000908 Douglas E. Hobson [Canada]Paroxysmal Kinesigenic Dyskinesia sans Dyskinesia or Paroxysmal Kinesigenic Dysesthesia?
000916 Louisa Clare Johnston [Royaume-Uni] ; Michael John Jackson [Royaume-Uni] ; Sarah Rose [Royaume-Uni] ; Andrew Christopher Mccreary [Pays-Bas] ; Peter Jenner [Royaume-Uni]Pardoprunox Reverses Motor Deficits but Induces Only Mild Dyskinesia in MPTP-Treated Common Marmosets
000929 Ray L. Watts [États-Unis] ; Kelly E. Lyons [États-Unis] ; Rajesh Pahwa [États-Unis] ; Kapil Sethi [États-Unis] ; Matthew Stern [États-Unis] ; Robert A. Hauser [États-Unis] ; Warren Olanow [États-Unis] ; Alex M. Gray [États-Unis] ; Bryan Adams [États-Unis] ; Nancy L. Earl [États-Unis]Onset of Dyskinesia with Adjunct Ropinirole Prolonged-Release or Additional Levodopa in Early Parkinson's Disease
000935 Kathryn A. Chung [États-Unis] ; Brenna M. Lobb [États-Unis] ; John G. Nutt [États-Unis] ; James Mcnames [États-Unis] ; Fay Horak [États-Unis]Objective Measurement of Dyskinesia in Parkinson's Disease using a Force Plate
000945 Szu-Chia Lai [Taïwan] ; Shih-Ming Jung [Taïwan] ; Padraic Grattan-Smith [Australie] ; Ella Sugo [Australie] ; Yen-Wen Lin [Taïwan] ; Rou-Shayn Chen [Taïwan] ; Chiung-Chu Chen [Taïwan] ; Yah-Huei Wu-Chou [Taïwan] ; Anthony E. Lang [Canada] ; Chin-Song Lu [Taïwan]Neuronal Intranuclear Inclusion Disease: Two Cases of Dopa-responsive Juvenile Parkinsonism with Drug-induced Dyskinesia
000958 JONG SAM BAIK [Corée du Sud] ; MYUNG SIK LEE [Corée du Sud]Movement Disorders Associated with Moyamoya Disease: A Report of 4 New Cases and a Review of Literatures
000960 Iria Cabo Lopez [Espagne] ; Pedro J. Garcia Ruiz [Espagne] ; Silvia Vázquez Fernandez Del Pozo [Espagne] ; Vicenta Sanchez Bernardos [Espagne]Motor Complications in Parkinson's Disease: Ten Year Follow-Up Study
000982 Galit Kleiner-Fisman [Canada] ; Andres Lozano [Canada] ; Elena Moro [Canada] ; Yu-Yan Poon [Canada] ; Anthony E. Lang [Canada]Long-Term Effect of Unilateral Pallidotomy on Levodopa-Induced Dyskinesia
000985 Elisabeth Wolf [Autriche] ; Klaus Seppi [Autriche] ; Regina Katzenschlager [Autriche] ; Guenter Hochschorner [Autriche] ; Gerhard Ransmayr [Autriche] ; Petra Schwingenschuh [Autriche] ; Erwin Ott [Autriche] ; Iris Kloiber [Autriche] ; Dietrich Haubenberger [Autriche] ; Eduard Auff [Autriche] ; Werner Poewe [Autriche]Long-Term Antidyskinetic Efficacy of Amantadine in Parkinson's Disease
000996 Alberto J. Espay [États-Unis] ; Dominic C. Paviour [Royaume-Uni] ; John D. O'Sullivan [Australie] ; Robert E. Schmidt [États-Unis] ; Fredy J. Revilla [États-Unis] ; Leo Verhagen Metman [États-Unis]Juvenile Levodopa-Responsive Parkinsonism with Early Orobuccolingual Dyskinesias and Cognitive Impairment
000A14 Asunci N Avila [Espagne] ; Plácida Maho [Espagne] ; Juan Bello [Espagne]Improvement of Orolingual Dyskinesia as a Remote Effect of Botulinum Toxin
000A59 Nune S. Yeghiazaryan [Italie, Arménie] ; Pasquale Striano [Italie] ; Patrizia Accorsi [Italie] ; Lorenzo Pinelli [Italie] ; Francesca Faravelli [Italie] ; Federico Zara [Italie] ; Carlo Minetti [Italie] ; Lucio Giordano [Italie]Familial Nonkinesigenic Paroxysmal Dyskinesia and Intracranial Calcifications: A New Syndrome?
000A76 Lior Greenbaum [Israël] ; Anna Alkelai [Israël] ; Amihai Rigbi [Israël] ; Yoav Kohn [Israël] ; Bernard Lerer [Israël]Evidence for Association of the GLI2 Gene with Tardive Dyskinesia in Patients with Chronic Schizophrenia
000A88 Tom H. Johnston [Canada] ; Anne Van Der Meij [Pays-Bas] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada]Effect of Histamine H2 Receptor Antagonism on Levodopa-Induced Dyskinesia in the MPTP-Macaque Model of Parkinson's Disease
000A94 Silvia Gil-Navarro [Espagne] ; Francisco Grandas [Espagne]Dyskinesia-Hyperpyrexia Syndrome: Another Parkinson's Disease Emergency
000B92 Pershia Samadi [Canada] ; Marc Morissette [Canada] ; Daniel Levesque [Canada] ; Thérèse Di Paolo [Canada]BDNF Levels Are Not Related with Levodopa-Induced Dyskinesias in MPTP Monkeys
000C12 Stephen Ku [États-Unis] ; Graham A. Glass [États-Unis]Age of Parkinson's Disease Onset as a Predictor for the Development of Dyskinesia
000C24 Pauline Belujon [États-Unis] ; Daniel J. Lodge [États-Unis] ; Anthony A. Grace [États-Unis]Aberrant Striatal Plasticity is Specifically Associated With Dyskinesia Following Levodopa Treatment
000C94 Christopher G. Goetz [États-Unis] ; John G. Nutt [États-Unis] ; Glenn T. Stebbins [États-Unis] ; Teresa A. Chmura [États-Unis]Teaching Program for the Unified Dyskinesia Rating Scale
000D05 Susan H. Fox [Canada] ; Rosalind Chuang [Canada] ; Jonathan M. Brotchie [Canada]Serotonin and Parkinson's Disease: On Movement, Mood, and Madness
000D21 Sasa R. Filipovie [Royaume-Uni] ; John C. Rothwell [Royaume-Uni] ; Bart P. Van De Warrenburg [Royaume-Uni, Pays-Bas] ; Kailash Bhatia [Royaume-Uni]Repetitive Transcranial Magnetic Stimulation for Levodopa-Induced Dyskinesias in Parkinson's Disease
000D75 Giovanni Fabbrini [Italie] ; Giovanni Defazio [Italie] ; Carlo Colosimo [Italie] ; Antonio Suppa [Italie] ; Maria Bloise [Italie] ; Alfredo Berardelli [Italie]Onset and Spread of Dyskinesias and Motor Symptoms in Parkinson's Disease
000D82 Diederik E. Tenback [Pays-Bas] ; Peter N. Van Harten [Pays-Bas] ; Jim Van Os [Pays-Bas, Royaume-Uni]Non-Therapeutic Risk Factors for Onset of Tardive Dyskinesia in Schizophrenia: A Meta-Analysis
000E04 Sebastian Paus [Allemagne] ; Franziska Gadow [Allemagne] ; Michael Knapp [Allemagne] ; Christine Klein [Allemagne] ; Thomas Klockgether [Allemagne] ; Ullrich Wüllner [Allemagne]Motor Complications in Patients Form the German Competence Network on Parkinson's Disease and the DRD3 Ser9Gly Polymorphism
000E19 Jane E. Alty [Australie] ; Benjamin G. Clissold [Australie] ; Craig D. Mccoll [Australie] ; Katrina A. Reardon [Australie] ; Mark Shiff [Australie] ; Peter A. Kempster [Australie]Longitudinal Study of the Levodopa Motor Response in Parkinson's Disease: Relationship Between Cognitive Decline and Motor Function
000E22 Hae-Won Shin [Corée du Sud] ; Mi J. Kim [Corée du Sud] ; Jong S. Kim [Corée du Sud] ; Myoung C. Lee [Corée du Sud] ; Sun J. Chung [Corée du Sud]Levosulpiride-Induced Movement Disorders
000E69 Susanne A. Schneider [Royaume-Uni] ; Coro Paisan-Ruiz [Royaume-Uni] ; Ines Garcia-Gorostiaga [Royaume-Uni, Espagne] ; Niall P. Quinn [Royaume-Uni] ; Yvonne G. Weber [Allemagne] ; Holger Lerche [Allemagne] ; John Hardy [Royaume-Uni] ; Kailash P. Bhatia [Royaume-Uni]GLUT1 Gene Mutations Cause Sporadic Paroxysmal Exercise-Induced Dyskinesias
000F51 C. Warren Olanow [États-Unis] ; Jean-Michel Gracies [États-Unis] ; Christopher G. Goetz [États-Unis] ; A. Jon Stoessl [Canada] ; Thomas Freeman [États-Unis] ; Jeffrey H. Kordower [États-Unis] ; James Godbold [États-Unis] ; Jose A. Obeso [Espagne]Clinical Pattern and Risk Factors for Dyskinesias Following Fetal Nigral Transplantation in Parkinson's Disease : A Double Blind Video-Based Analysis
000F65 Neema Kasravi [Canada] ; Mandar S. Jog [Canada]Botulinum Toxin in the Treatment of Lingual Movement Disorders
000F73 William F. Abdo [Pays-Bas] ; Bastiaan R. Bloem [Pays-Bas] ; Jeroen J. Eijk [Pays-Bas] ; Alexander C. Geurts [Pays-Bas] ; Nens Van Alfen [Pays-Bas] ; Bart P. C. Van De Warrenburg [Pays-Bas]Atypical Dystonic Shoulder Movements Following Neuralgic Amyotrophy
001034 Fabrizio Stocchi [Italie] ; Michele Tagliati [États-Unis] ; C. Warren Olanow [États-Unis]Treatment of Levodopa-Induced Motor Complications
001043 Christopher G. Goetz [États-Unis] ; John G. Nutt [États-Unis] ; Glenn T. Stebbins [États-Unis]The Unified Dyskinesia Rating Scale : Presentation and Clinimetric Profile
001054 Naomi P. Visanji [Canada] ; Rob M. A. De Bie [Canada] ; Tom H. Johnston [Canada] ; Andrew C. Mccreary [Pays-Bas] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada]The Nociceptin/Orphanin FQ (NOP) Receptor Antagonist J-113397 Enhances the Effects of Levodopa in the MPTP-Lesioned Nonhuman Primate Model of Parkinson's Disease
001067 Timothy J. Kleinig [Australie] ; Philip D. Thompson [Australie] ; Walid Matar [Australie] ; Andrew Duggins [Australie] ; Thomas E. Kimber [Australie] ; John G. Morris [Australie] ; Christopher S. Kneebone [Australie] ; Peter C. Blumbergs [Australie]The Distinctive Movement Disorder of Ovarian Teratoma-Associated Encephalitis
001070 Christos Tsironis [Grèce] ; Marios Marselos [Grèce] ; Angelos Evangelou [Grèce] ; Spiridon Konitsiotis [Grèce]The Course of Dyskinesia Induction by Different Treatment Schedules of Levodopa in Parkinsonian Rats : Is Continuous Dopaminergic Stimulation Necessary?
001073 Anthony H. V. Schapira [Royaume-Uni]The Clinical Relevance of Levodopa Toxicity in the Treatment of Parkinson's Disease
001125 Peter Jenner [Royaume-Uni]Preventing and Controlling Dyskinesia in Parkinson's Disease : A View of Current Knowledge and Future Opportunities
001137 Christopher G. Goetz [États-Unis] ; Eugene Laska [États-Unis] ; Christine Hicking [Allemagne] ; Philippe Damier [France] ; Thomas Müller [Allemagne] ; John Nutt [États-Unis] ; C. Warren Olanow [États-Unis] ; Olivier Rascol [France] ; Hermann Russ [Allemagne]Placebo Influences on Dyskinesia in Parkinson's Disease
001141 John G. Nutt [États-Unis]Pharmacokinetics and Pharmacodynamics of Levodopa
001146 Thomas L. Shirley [États-Unis] ; Lekha M. Rao [États-Unis] ; Ellen J. Hess [États-Unis] ; H. A. Jinnah [États-Unis]Paroxysmal Dyskinesias in Mice
001155 Pierre J. Blanchet [Canada] ; Romana Popovici [Canada] ; Francine Guitard [Canada] ; Pierre H. Rompre [Canada] ; Claude Lamarche [Canada] ; Gilles J. Lavigne [Canada]Pain and Denture Condition in Edentulous Orodyskinesia : Comparisons with Tardive Dyskinesia and Control Subjects
001167 Maryka Quik [États-Unis] ; Kathryn O'Leary [États-Unis] ; Caroline M. Tanner [États-Unis]Nicotine and Parkinson's Disease : Implications for Therapy
001190 Paolo Calabresi [Italie] ; Massimiliano Di Filippo [Italie] ; Veronica Ghiglieri [Italie] ; Barbara Picconi [Italie]Molecular Mechanisms Underlying Levodopa-Induced Dyskinesia
001264 Christopher G. Goetz [États-Unis] ; Sue Leurgans [États-Unis] ; Vanessa K. Hinson [États-Unis] ; Lucia M. Blasucci [États-Unis] ; Jennifer Zimmerman [États-Unis] ; WENQING FAN [États-Unis] ; Tiffany Nguyen [États-Unis] ; Ann Hsu [États-Unis]Evaluating Parkinson's Disease Patients at Home : Utility of Self-Videotaping for Objective Motor, Dyskinesia, and ON-OFF Assessments
001273 Pedro J. Garcia Ruiz ; Angel Sesar Ignacio ; Begona Ares Pensado ; Alfonso Castro Garcia ; Fernando Alonso Frech ; Mercedes Alvarez Lopez ; José Arbelo Gonzalez ; Joan Baiges Octavio ; Juan Andrés Burguera Herandez ; Matilde Calopa Garriga ; Dulce Campos Blanco ; Belén Castano Garcia ; Manuel Carballo Cordero ; José Chacon Pena ; Anna Espino Ibanez ; Aranzazu Gorospe Onisalde ; Santiago Gimenez-Roldan ; Pilar Granes Ibanez ; Jorge Hernandez Vara ; Ramon Ibanez Alonso ; Félix Javier Jimenez Jimenez ; Jerzy Krupinski ; Jaime Kulisevsky Bojarsky ; Inés Legarda Ramirez ; Elena Lezcano Garcia ; Juan Carlos Martinez-Castrillo ; Dolores Mateo Gonzalez ; Francesc Miquel Rodriguez ; Pablo Mir Rivera ; Elena Munoz Fargas ; José Obeso Inchausti ; Jesus Olivares Romero ; José Olive Plana ; Pilar Otermin Vallejo ; Berta Pascual Sedano ; Victor Perez De Colosia Rama ; Isabel Perez Lopez-Fraile ; Albert Planas Cornes ; Victor Puente Periz ; Maria Cruz Rodriguez Oroz ; Dolores Sevillano Garcia ; Pilar Solis Perez ; José Suarez Munoz ; Julia Vaamonde Gamo ; Caridad Valero Merino ; Francesc Valldeoriola Serra ; José Miguel Velazquez Perez ; Rosa Yanez Bana ; Ivana Zamarbide CapdeponEfficacy of Long-Term Continuous Subcutaneous Apomorphine Infusion in Advanced Parkinson's Disease with Motor Fluctuations : A Multicenter Study
001274 John G. Nutt [États-Unis] ; Steven A. Gunzler [États-Unis] ; Trish Kirchhoff [États-Unis] ; Penelope Hogarth [États-Unis] ; Jerry L. Weaver [États-Unis] ; Michael Krams [États-Unis] ; Brenda Jamerson [États-Unis] ; Frank S. Menniti [États-Unis] ; Jaren W. Landen [États-Unis]Effects of a NR2B Selective NMDA Glutamate Antagonist, CP-101,606, on Dyskinesia and Parkinsonism
001288 Shen-Yang Lim [Australie] ; Michael J. Farrell [Australie] ; Stephen J. Gibson [Australie] ; Robert D. Helme [Australie] ; Anthony E. Lang [Canada] ; Andrew H. Evans [Australie]Do Dyskinesia and Pain Share Common Pathophysiological Mechanisms in Parkinson's Disease?
001291 Abdesslem Khiat [Canada] ; Yevgeniy Kuznetsov [Canada] ; Pierre J. Blanchet [Canada] ; Yvan Boulanger [Canada]Diffusion-Weighted Imaging and Magnetization Transfer Imaging of Tardive and Edentulous Orodyskinesia
001296 Jan Herzog [Allemagne] ; Oliver Pogarell [Allemagne] ; Marcus O. Pinsker [Allemagne] ; Andreas Kupsch [Allemagne] ; Wolfgang H. Oertel [Allemagne] ; Olle Lindvall [Suède] ; Günther Deuschl [Allemagne] ; Jens Volkmann [Allemagne]Deep Brain Stimulation in Parkinson's Disease Following Fetal Nigral Transplantation
001439 Robert A. Hauser [États-Unis] ; Olivier Rascol [France] ; Amos D. Korczyn [Israël] ; A. Jon Stoessl [Canada] ; Ray L. Watts [États-Unis] ; Werner Poewe [Autriche] ; Peter P. De Deyn [Belgique] ; Anthony E. Lang [Canada]Ten-Year Follow-Up of Parkinson's Disease Patients Randomized to Initial Therapy with Ropinirole or Levodopa
001440 Ikwunga Wonodi [États-Unis] ; Gloria Reeves [États-Unis] ; Dana Carmichael [États-Unis] ; Ilene Verovsky [États-Unis] ; Matthew T. Avila [États-Unis] ; Amie Elliott [États-Unis] ; L. Elliot Hong [États-Unis] ; Helene M. Adami [États-Unis] ; Gunvant K. Thaker [États-Unis]Tardive dyskinesia in children treated with atypical antipsychotic medications
001451 Penelope J. Hallett [États-Unis] ; J. M. Brotchie [Canada]Striatal delta opioid receptor binding in experimental models of Parkinson's disease and dyskinesia
001453 J. Herzog [Allemagne] ; M. Pinsker [Allemagne] ; M. Wasner [Allemagne] ; F. Steigerwald [Allemagne] ; S. Wailke [Allemagne] ; G. Deuschl [Allemagne] ; J. Volkmann [Allemagne]Stimulation of subthalamic fibre tracts reduces dyskinesias in STN-DBS
001455 Ali Samii [États-Unis] ; Valerie E. Kelly [États-Unis] ; Jefferson C. Slimp [États-Unis] ; Anne Shumway-Cook [États-Unis] ; Robert Goodkin [États-Unis]Staged unilateral versus bilateral subthalamic nucleus stimulator implantation in Parkinson disease
001475 Christopher G. Goetz [États-Unis] ; Philippe Damier [France] ; Christine Hicking [Allemagne] ; Eugene Laska [États-Unis] ; Thomas Müller [Allemagne] ; C. Warren Olanow [États-Unis] ; Olivier Rascol [France] ; Hermann Russ [Allemagne]Sarizotan as a treatment for dyskinesias in Parkinson's disease : A double-blind placebo-controlled trial
001493 Vincent Paille [France] ; Vincent Henry [France] ; Laurent Lescaudron [France] ; Philippe Brachet [France] ; Philippe Damier [France]Rat model of Parkinson's disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias
001509 Yevgeniy Kuznetsov [Canada] ; Abdesslem Khiat [Canada] ; Pierre J. Blanchet [Canada] ; Yvan Boulanger [Canada]Proton magnetic resonance spectroscopy study of dyskinesia patients
001548 Deborah A. Hall [États-Unis] ; Julie Parsons [États-Unis] ; Tim Benke [États-Unis]Paroxysmal nonkinesigenic dystonia and celiac disease
001557 David Epstein [États-Unis] ; Marc Difazio [États-Unis]Orofacial automatisms induced by acute withdrawal from high-dose midazolam mimicking nonconvulsive status epilepticus in a child
001572 Maria Fulvia De Leva [Italie] ; Andrea Varrone [Italie] ; Alessandro Filla [Italie] ; Mario Quarantelli [Italie] ; Leonilda Bilo [Italie] ; Valeria Piscitelli [Italie] ; Elena Salvatore [Italie] ; Sara Ammendola [Italie] ; Salvatore Striano [Italie] ; Giuseppe De Michele [Italie] ; Vincenzo Bonavita [Italie] ; Sabina Pappata [Italie]Neuroimaging Follow-Up in a Case of Rasmussen's Encephalitis with Dyskinesias
001609 Christopher Kenney [États-Unis] ; Christine Hunter [États-Unis] ; Joseph Jankovic [États-Unis]Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders
001614 Anthony P. Nicholas [États-Unis]Levodopa-induced hyperactivity in mice treated with 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridine
001615 Giovanni Fabbrini [Italie] ; Jonathan M. Brotchie [Canada] ; Francisco Grandas [Espagne] ; Masahiro Nomoto [Japon] ; Christopher G. Goetz [États-Unis]Levodopa-induced dyskinesias
001655 Julian P. Rodrigues [Australie] ; Susan E. Walters [Australie] ; Peter Watson [Australie] ; Rick Stell [Australie] ; Frank L. Mastaglia [Australie]Globus pallidus stimulation improves both motor and nonmotor aspects of quality of life in advanced parkinson's disease
001794 Regina Katzenschlager [Royaume-Uni, Autriche] ; Michael J. Jackson [Royaume-Uni] ; Sarah Rose [Royaume-Uni] ; Kim Stockwell [Royaume-Uni] ; Kayhan A. Tayarani-Binazir [Royaume-Uni] ; Mohammed Zubair [Royaume-Uni] ; Lance A. Smith [Royaume-Uni] ; Peter Jenner [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni]Antiparkinsonian activity of L-propyl-L-leucyl-glycinamide or melanocyte-inhibiting factor in MPTP-treated common marmosets
001863 Susan H. Fox [Canada] ; Anthony E. Lang [Canada] ; Jonathan M. Brotchie [Canada]Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies : Keys to success and roads to failure
001900 Esther Brusse [Pays-Bas] ; Inge De Koning [Pays-Bas] ; Anneke Maat-Kievit [Pays-Bas] ; Ben A. Oostra [Pays-Bas] ; Peter Heutink [Pays-Bas] ; John C. Van Swieten [Pays-Bas]Spinocerebellar ataxia associated with a mutation in the fibroblast growth factor 14 gene (SCA27) : A new phenotype
001933 Laura Silveira-Moriyama [Royaume-Uni] ; Andrew H. Evans [Royaume-Uni] ; Regina Katzenschlager [Royaume-Uni, Autriche] ; Andrew Lees (neurologue) [Royaume-Uni]Punding and dyskinesias
001946 Marc Morissette [Canada] ; Mehdi Dridi [Canada] ; Frédéric Calon [Canada] ; Abdallah Hadj Tahar [Canada] ; Leonard T. Meltzer [États-Unis] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada]Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in Parkinsonian monkeys : Implication of preproenkephalin
001967 Wolfgang H. Oertel [Allemagne] ; Erik Wolters [Pays-Bas] ; Cristina Sampaio [Portugal] ; Santiago Gimenez-Roldan [Espagne] ; Bruno Bergamasco [Italie] ; Max Dujardin [France] ; Donald G. Grosset [Royaume-Uni] ; Guy Arnold [Allemagne] ; Klaus L. Leenders [Pays-Bas] ; Hans-Peter Hundemer [États-Unis] ; Alberto Lledo [États-Unis] ; Andrew Wood [États-Unis] ; Paul Frewer [États-Unis] ; Johannes Schwarz [Allemagne]Pergolide versus levodopa monotherapy in early Parkinson's disease patients : The PELMOPET study
001993 Matthew A. Brodsky [États-Unis] ; Penelope Hogarth [États-Unis] ; John G. Nutt [États-Unis]OFF-off rebound dyskinesia in subthalamic nucleus deep brain stimulation of parkinson's disease
001A33 Spiros Konitsiotis [Grèce] ; Sofia Pappa [Grèce] ; Christos Mantas [Grèce] ; Venos Mavreas [Grèce]Levetiracetam in tardive dyskinesia : An open label study
001A49 Valerie Cochen De Cock [France] ; Frederic Bourdain [France] ; Emmanuelle Apartis [France] ; Jean Marc Trocello [France] ; Emmanuel Roze [France] ; Marie Vidailhet [France]Interictal myoclonus with paroxysmal kinesigenic dyskinesia
001A72 Jordi Gomez-Ramirez [Canada] ; Tom H. Johnston [Canada] ; Naomi P. Visanji [Canada] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada]Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of parkinson's disease
001A81 William Bara-Jimenez [États-Unis] ; Tzvetelina D. Dimitrova [États-Unis] ; Abdullah Sherzai [États-Unis] ; Murat Aksu [États-Unis] ; Thomas N. Chase [États-Unis]Glutamate release inhibition ineffective in levodopa-induced motor complications
001A84 Katie Kompoliti [États-Unis] ; Christopher G. Goetz [États-Unis] ; Mary Morrissey [États-Unis] ; Sue Leurgans [États-Unis]Gilles de la tourette syndrome : Patient's knowledge and concern of adverse effects
001A86 Judith A. Strong [États-Unis] ; Arif Dalvi [États-Unis] ; Fredy J. Revilla [États-Unis] ; Alok Sahay [États-Unis] ; Frederick J. Samaha [États-Unis] ; Jeffrey A. Welge [États-Unis] ; JIANHUA GONG [États-Unis] ; Maureen Gartner [États-Unis] ; XIA YUE [États-Unis] ; LEI YU [États-Unis]Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease
001B08 Daniel Tarsy [États-Unis] ; Ross J. Baldessarini [États-Unis]Epidemiology of tardive dyskinesia : Is risk declining with modern antipsychotics?
001B10 Diana Apetauerova [États-Unis] ; R. Kevin Ryan [États-Unis] ; Susie I. Ro [États-Unis] ; Jeffrey Arle [États-Unis] ; Jay Shils [États-Unis] ; Efstathios Papavassiliou [États-Unis] ; Daniel Tarsy [États-Unis]End of day dyskinesia in advanced Parkinson's disease can be eliminated by bilateral subthalamic nucleus or globus pallidus deep brain stimulation
001B11 Alexei Korchounov [Allemagne, Égypte] ; Gregory Bogomazov [Russie]Employment, medical absenteeism, and disability perception in Parkinson's disease : A pilot double-blind, randomized, placebo-controlled study of entacapone adjunctive therapy
001B50 Olivier Rascol [France] ; David J. Brooks [Royaume-Uni] ; Amos D. Korczyn [Israël] ; Peter P. De Deyn [Belgique] ; Carl E. Clarke [Royaume-Uni] ; Anthony E. Lang [Canada] ; Mona Abdalla [Royaume-Uni]Development of dyskinesias in a 5-year trial of ropinirole and L-dopa
001B70 Kazumichi Yamada [Japon] ; Satoshi Goto [Japon] ; Naohiro Soyama [Japon] ; Osamu Shimoda [Japon] ; Mareina Kudo [Japon] ; Jun-Ichi Kuratsu [Japon] ; Nagako Murase [Japon] ; Ryuji Kaji [Japon]Complete suppression of paroxysmal nonkinesigenic dyskinesia by globus pallidus internus pallidal stimulation
001B76 Concepcio Marin [Espagne] ; Esther Aguilar [Espagne] ; José A. Obeso [Espagne]Coadministration of entacapone with levodopa attenuates the severity of dyskinesias in hemiparkinsonian rats
001B81 Elka Stefanova [Serbie] ; Ana Djarmati [Allemagne] ; Dragana Momcilovic [Serbie] ; Natasa Dragasevic [Serbie] ; Marina Svetel [Serbie] ; Christine Klein [Allemagne] ; Vladimir S. Kostic [Serbie]Clinical characteristics of paroxysmal nonkinesigenic dyskinesia in Serbian family with Myofibrillogenesis Regulator 1 gene mutation
001B84 Servane Mouton [France] ; Jing Xie-Brustolin [France] ; Patrick Mertens [France] ; Gustavo Polo [France] ; Philippe Damier [France] ; Emmanuel Broussolle [France] ; Stéphane Thobois [France]Chorea induced by globus pallidus externus stimulation in a dystonic patient
001C07 Peter N. Van Harten [Pays-Bas] ; Ad Hovestadt [Pays-Bas]Botulinum toxin as a treatment for tardive dyskinesia
001C10 Cornelius G. Bachmann [Allemagne] ; Claudia Trenkwalder [Allemagne]Body weight in patients with Parkinson's disease
001C35 Michael P. Hill [Royaume-Uni] ; Paula Ravenscroft [Royaume-Uni] ; Steven G. Mcguire [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Catherine Rochat [France] ; Mark J. Millan [France]Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets : Mediation by D2, not D3, dopamine receptors
001C51 Jonathan Halford [États-Unis] ; Gandis Mazeika [États-Unis] ; Susan Slifer [États-Unis] ; Marcy Speer [États-Unis] ; Ann M. Saunders [États-Unis] ; Warren J. Strittmatter [États-Unis] ; Joel C. Morgenlander [États-Unis]APOE2 allele increased in tardive dyskinesia
001C54 Erie Chuen-Hian Lim [Singapour] ; Einar P. V. Wilder-Smith [Singapour] ; Raymond Chee-Seong Seet [Singapour]A blessing in disguise : Resolution of tardive dyskinesia with development of cervical myelitis
001C67 Nathan E. Crone [États-Unis] ; H. A. Jinnah [États-Unis] ; Stephen G. Reich [États-Unis]Wilson's disease presenting with an unusual cough
001C87 Monty A. Silverdale [Royaume-Uni] ; S. L. Nicholson [Royaume-Uni] ; A. R. Crossman [Royaume-Uni] ; J. M. Brotchie [Canada]Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of parkinson's disease
001D01 Francisca Sueli Monte [Brésil] ; Francisco Pereira Da Silva-Junior [Brésil] ; Pedro Braga-Neto [Brésil] ; Miguel Angelo Nobre E Souza [Brésil] ; Veralice Meireles Sales De Bruin [Brésil]Swallowing abnormalities and dyskinesia in Parkinson's disease
001D04 Antonio Pisani [Italie] ; Diego Centonze [Italie] ; Giorgio Bemardi [Italie] ; Paolo Calabresi [Italie]Striatal synaptic plasticity : Implications for motor learning and Parkinson's disease
001D22 Leo Verhagen Metman [États-Unis] ; Shaun T. O'Leary [États-Unis]Role of surgery in the treatment of motor complications
001D26 Costas Michaelides [États-Unis] ; Manisha Thakore-James [États-Unis] ; Raymon Durso [États-Unis]Reversible withdrawal dyskinesia associated with quetiapine
001D55 Marc Engelen [Pays-Bas] ; Marina A. J. Tijssen [Pays-Bas]Paroxysmal non-kinesigenic dyskinesia in antiphospholipid syndrome
001D66 YUE HUANG [Australie] ; Raymond Garrick [Australie] ; Raymond Cook [Australie] ; Dudley O'Sullivan [Australie] ; John Morris [Australie] ; Glenda M. Halliday [Australie]Pallidal stimulation reduces treatment-induced dyskinesias in "minimal-change" multiple system atrophy
001D68 Cheryl Waters [États-Unis]Other pharmacological treatments for motor complications and dyskinesias
001D70 Theresa A. Zesiewicz [États-Unis] ; Kelly L. Sullivan [États-Unis] ; John L. Maldonado [États-Unis] ; William O. Tatum [États-Unis] ; Robert A. Hauser [États-Unis]Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease
001D79 Jonathan M. Brotchie [Canada]Nondopaminergic mechanisms in levodopa-induced dyskinesia
001D92 Joseph Jankovic [États-Unis]Motor fluctuations and dyskinesias in Parkinson's disease : Clinical manifestations
001D96 Nicte I. Mejia [États-Unis] ; Joseph Jankovic [États-Unis]Metoclopramide-induced tardive dyskinesia in an infant
001E31 Evzen Ruzicka [République tchèque] ; Dusan Urgosik [République tchèque] ; Robert Jech [République tchèque] ; Jan Roth [République tchèque] ; Josef Vymazal [République tchèque] ; Petr Mecir [République tchèque] ; Vilibald Vladyka [République tchèque]Hemiparkinsonism and levodopa-induced dyskinesias after focal nigral lesion
001E56 Girutz Linazasoro [Espagne] ; Nadège Van Blercom [Espagne] ; Asier Lasa [Espagne] ; José Manuel Fernandez [Espagne] ; Inés Aranzabal [Espagne]Etiological and therapeutical observations in a case of belly dancer's dyskinesia
001E63 William Bara-Jimenez [États-Unis] ; Francesco Bibbiani [États-Unis] ; Michael J. Morris [États-Unis] ; Tzvetelina Dimitrova [États-Unis] ; Abdullah Sherzai [États-Unis] ; Maral M. Mouradian [États-Unis] ; Thomas N. Chase [États-Unis]Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease
001E69 Pershia Samadi [Canada] ; Laurent Gregoire [Canada] ; Arash Rassoulpour [États-Unis] ; Paolo Guidetti [Canada] ; Emanuela Izzo [Italie] ; Robert Schwarcz [États-Unis] ; Paul J. Bedard [Canada]Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in parkinsonian monkeys
001E71 Svenja Happe [Allemagne] ; Martin Sommer [Allemagne] ; Johannes Meller [Allemagne] ; Claudia Trenkwalder [Allemagne] ; Walter Paulus [Allemagne]Dyskinesias due to intravenous apomorphine abuse in a patient without basal ganglia disorder
001E89 Regina Katzenschlager [Royaume-Uni, Autriche] ; Andrew Hughes [Australie] ; Andrew Evans [Royaume-Uni] ; Alice J. Manson [Royaume-Uni] ; Marion Hoffman [Australie] ; Lesley Swinn [Royaume-Uni] ; Hilary Watt [Royaume-Uni] ; Kailash Bhatia [Royaume-Uni] ; Niall Quinn [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni]Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease : A prospective study using single-dose challenges
001F01 Michael H. Pourfar [États-Unis] ; Renzo Guerrini [Italie] ; Dominique Parain [France] ; Steven J. Frucht [États-Unis]Classification conundrums in paroxysmal dyskinesias : A new subtype or variations on classic themes?
001F45 Tatiana Witjas [France] ; Christelle Baunez [France] ; Jean Marc Henry [France] ; Marie Delfini [France] ; Jean Regis [France] ; André Ali Cherif [France] ; Jean Claude Peragut [France] ; Jean Philippe Azulay [France]Addiction in Parkinson's disease : Impact of subthalamic nucleus deep brain stimulation
001F46 Spiros Konitsiotis [Grèce] ; Sofia Pappa [Grèce] ; Christos Mantas [Grèce] ; Venos Mavreas [Grèce]Acute reversible dyskinesia induced by mirtazapine
001F68 Christoph Schrader [Allemagne] ; Thomas Peschel [Allemagne] ; Michael Petermeyer [Allemagne] ; Reinhard Dengler [Allemagne] ; Dieter Hellwig [Allemagne]Unilateral deep brain stimulation of the internal globus pallidus alleviates tardive dyskinesia
001F79 Matthew J. Hansard [Royaume-Uni] ; Lance A. Smith [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Sharon C. Cheetham [Royaume-Uni] ; Peter Jenner [Royaume-Uni]The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates
001F80 Leo Verhagen Metman [États-Unis] ; Brian Myre [États-Unis] ; Niek Verwey [États-Unis] ; Sharon Hassin-Baer [Israël] ; Jean Arzbaecher [États-Unis] ; Diane Sierens [États-Unis] ; Roy Bakay [États-Unis]Test-retest reliability of UPDRS-III, dyskinesia scales, and timed motor tests in patients with advanced Parkinson's disease: An argument against multiple baseline assessments
002017 Jan L. De Bleecker [Belgique] ; Veerle L. Vervaet [Belgique] ; Angela De Sarro [Italie]Reversible orofacial dyskinesia after ofloxacin treatment
002032 Connie Marras [Canada] ; Anthony Lang [Canada] ; Murray Krahn [Canada] ; George Tomlinson [Canada] ; Gary Naglie [Canada]Quality of life in early Parkinson's disease: Impact of dyskinesias and motor fluctuations
002043 Pierre J. Blanchet [Canada] ; Ossob Abdillahi [Canada] ; Chantale Beauvais [Canada] ; Pierre H. Rompre [Canada] ; Gilles J. Lavigne [Canada]Prevalence of spontaneous oral dyskinesia in the elderly: A reappraisal
002091 Lance A. Smith [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Ghassan Al-Barghouthy [Royaume-Uni] ; Sarah Rose [Royaume-Uni] ; Mikko Kuoppamaki [Royaume-Uni, États-Unis] ; Warren Olanow [Finlande] ; Peter Jenner [Royaume-Uni]Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naïve primates
002111 Neeraj Kumar [États-Unis] ; Jay A. Van Gerpen [États-Unis] ; James H. Bower [États-Unis] ; J. Eric Ahlskog [États-Unis]Levodopa-dyskinesia incidence by age of Parkinson's disease onset
002230 Hazem A. Eltahawy [Canada] ; Anthony Feinstein [Canada] ; Farouk Khan [Canada] ; Jean Saint-Cyr [Canada] ; Anthony E. Lang [Canada] ; Andres M. Lozano [Canada]Bilateral globus pallidus internus deep brain stimulation in tardive dyskinesia: A case report
002254 Yoshiaki Furukawa [Canada] ; James J. Filiano [États-Unis] ; Stephen J. Kish [Canada]Amantadine for levodopa-induced choreic dyskinesia in compound heterozygotes for GCH1 mutations
002260 Stéphane Thobois [France] ; JING XIE [France] ; Helena Mollion [France] ; Isabelle Benatru [France] ; Emmanuel Broussolle [France]Adrafinil-induced orofacial dyskinesia
002306 Pedro J. Garcia-Ruiz [Espagne] ; Vicente Villanueva [Espagne] ; Eva Gutierrez-Delicado [Espagne] ; Amaia Echeverria [Espagne] ; Antonio Perez-Higueras [Espagne] ; José M. Serratosa [Espagne]Subthalamic lesion and paroxysmal tonic spasms
002310 Sylvie Raoul [France] ; Mirella Faighel [France] ; Isabelle Rivier [France] ; Marc Verin [France] ; Youenn Lajat [France] ; Philippe Damier [France]Staged lesions through implanted deep brain stimulating electrodes: A new surgical procedure for treating tremor or dyskinesias
002391 Michael P. Hill [Royaume-Uni] ; Erwan Bezard [France] ; Steven G. Mcguire [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Canada] ; Ann Michel [Belgique] ; Renee Grimee [Belgique] ; Henrik Klitgaard [Belgique]Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset
002401 Pedro Gonzalez-Alegre [États-Unis] ; Zakaria Ammache [États-Unis] ; Patricia H. Davis [États-Unis] ; Robert L. Rodnitzky [États-Unis]Moyamoya-induced paroxysmal dyskinesia
002450 Juha-Matti Savola [Finlande] ; Michael Hill [Royaume-Uni] ; Mia Engstrom [Finlande] ; Hannele Merivuori [Finlande] ; Siegfried Wurster [Finlande] ; Steven G. Mcguire [Royaume-Uni] ; Susan H. Fox [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni]Fipamezole (JP-1730) is a potent α2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease
002465 Kathy Steece-Collier [États-Unis] ; Timothy J. Collier [États-Unis] ; Paul D. Danielson [États-Unis] ; Roger Kurlan [États-Unis] ; David M. Yurek [États-Unis] ; John R. Jr Sladek [États-Unis]Embryonic mesencephalic grafts increase levodopa-induced forelimb hyperkinesia in Parkinsonian rats
002472 Lance A. Smith [Royaume-Uni] ; Michael J. Jackson ; Matthew J. Hansard ; Eleni Maratos ; Peter JennerEffect of pulsatile administration of Levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: Effect of dose, frequency of administration, and brain exposure
002514 Nancy Belanger [Canada] ; Laurent Gregoire [Canada] ; ABDALLAH HADJ TAHAR [Canada] ; Paul J. Bedard [Canada]Chronic treatment with small doses of cabergoline prevents Dopa-induced dyskinesias in Parkinsonian monkeys
002519 Frédéric Calon [Canada] ; Marc Morissette [Canada] ; Ali H. Rajput [Canada] ; Oleh Hornykiewicz [Canada, Autriche] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada]Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications
002532 Noël L. W. Keijsers [Pays-Bas] ; Martin W. I. M. Horstink [Pays-Bas] ; Stan C. A. M. Gielen [Pays-Bas]Automatic assessment of levodopa-induced dyskinesias in daily life by neural networks
002542 Graham T. A. Warner [Royaume-Uni] ; John H. Mcauley [Royaume-Uni]Alcohol-induced paroxysmal nonkinesogenic dyskinesia after pallidal hypoxic insult
002582 Ronald K. B. Pearce [Royaume-Uni] ; Lance A. Smith [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Tara Banerji [Royaume-Uni] ; Jorgen Scheel-Krüger [Danemark] ; Peter Jenner [Royaume-Uni]The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP-treated and levodopa-primed common marmosets
002585 Louis C. Tan [États-Unis] ; Peter H. Protell [États-Unis] ; J. William Langston [États-Unis] ; Daniel M. Togasaki [États-Unis]The Hyperkinetic Abnormal Movements Scale: A tool for measuring levodopa-induced Abnormal Movements in squirrel monkeys
002590 Rebecka Klintenberg [Suède] ; Lars Gunne [Suède] ; Per E. Andren [Suède]Tardive dyskinesia model in the common marmoset
002601 Susan H. Fox [Royaume-Uni] ; Brian Henry [Royaume-Uni] ; Michael Hill [Royaume-Uni] ; Alan Crossman [Royaume-Uni] ; Jonathan Brotchie [Royaume-Uni]Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease
002616 Jaishri Blakeley [États-Unis] ; Joseph Jankovic [États-Unis]Secondary paroxysmal dyskinesias
002626 Lance A. Smith [Royaume-Uni] ; Banu C. Tel [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Matthew J. Hansard [Royaume-Uni] ; Rogelio Braceras [Royaume-Uni] ; Céline Bonhomme [France] ; Claire Chezaubernard [France] ; Susanna Del Signore [France] ; Sarah Rose [Royaume-Uni] ; Peter Jenner [Royaume-Uni]Repeated administration of Piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: A behavioural and biochemical investigation
002686 Craig D. Mccoll [Australie] ; Katrina A. Reardon [Australie] ; Mark Shiff [Australie] ; Peter A. Kempster [Australie]Motor response to levodopa and the evolution of motor fluctuations in the first decade of treatment of Parkinson's disease
002691 Jong-Hoon Kim [Corée du Sud] ; HEE YEON JUNG [Corée du Sud] ; UNG GU KANG [Corée du Sud] ; SEONG HOON JEONG [Corée du Sud] ; YONG MIN AHN [Corée du Sud] ; Hee-Jung Byun [Corée du Sud] ; Kyoo-Seob Ha [Corée du Sud] ; YONG SIK KIM [Corée du Sud]Metric characteristics of the Drug-Induced extrapyramidal Symptoms Scale (DIEPSS): A practical combined rating Scale for drug-induced movement disorders
002707 Gurutz Linazasoro [Espagne] ; Nadege Van Blercom [Espagne] ; Asier Lasa [Espagne]Levodopa-induced ocular dyskinesias in Parkinson's disease
002708 Petr Kanovsky [République tchèque] ; Dagmar Kubova [République tchèque] ; Martin Bares [République tchèque] ; Hana Hortova [République tchèque] ; Hana Streitova [République tchèque] ; Ivan Rektor [République tchèque] ; Vladimir Znojil [République tchèque]Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: Results of a two-year, prospective follow-up
002709 Jong-Min Kim [Corée du Sud] ; KI HYEONG LEE [Corée du Sud] ; Yoon-La Choi [Corée du Sud] ; GI YEONG CHOE [Corée du Sud] ; Beom S. Jeon [Corée du Sud]Levodopa-induced dyskinesia in an autopsy-proven case of progressive supranuclear palsy
002738 Chiung-Chu Chen [Taïwan] ; Shih-Tseng Lee [Taïwan] ; Tony Wu [Taïwan] ; Chi-Jen Chen [Taïwan] ; Chin-Chang Huang [Taïwan] ; Chin-Song Lu [Taïwan]Hemiballism after subthalamotomy in patients with Parkinson's disease: Report of 2 cases
002743 Sian D. Spacey [Royaume-Uni, Canada] ; Enza-Maria Valente [Royaume-Uni, Italie] ; Gurusidheshwar M. Wali [Inde] ; Thomas T. Warner [Royaume-Uni] ; Paul R. Jarman [Royaume-Uni] ; Anthony H. V. Schapira [Royaume-Uni] ; Peter H. Dixon [Royaume-Uni] ; Mary B. Davis [Royaume-Uni] ; Kailash P. Bhatia [Royaume-Uni] ; Nicholas W. Wood [Royaume-Uni]Genetic and clinical heterogeneity in paroxysmal kinesigenic dyskinesia: Evidence for a third EKD gene
002759 Thomas D. Bird [États-Unis]Familial dyskinesia and facial myokymia
002776 Karen Stergaard [Danemark] ; Niels Sunde [Danemark] ; Erik Dupont [Danemark]Effects of bilateral stimulation of the subthalamic nucleus in patients with severe Parkinson's disease and motor fluctuations
002797 J. E. Rice [Australie] ; R. Antic [Australie] ; Philip D. Thompson [Australie]Disordered respiration as a levodopa-induced dyskinesia in Parkinson's disease
002824 Anne Thiriaux [France] ; Anne De St Martin [France] ; Laurent Vercueil [France] ; Fabrice Battaglia [France] ; Jean-Paul Armspach [France] ; Edouard Hirsch [France] ; Christian Marescaux [France] ; Izzie J. Namer [France]Co-occurrence of infantile epileptic seizures and childhood paroxysmal choreoathetosis in one family: Clinical, EEG, and SPECT characterization of episodic events
002826 Azi H. Rajput [Canada] ; Mark E. Fenton [Canada] ; Sam Birdi [Canada] ; Rob Macaulay [Canada] ; David George [Canada] ; Bohdar Rozdilsky [Canada] ; Lee C. Ang [Canada] ; Ambikaipakan Senthilselvan [Canada] ; Oleh Hornykiewicz [Autriche]Clinical-pathological study of levodopa complications
002851 Mikko Kuoppam Ki [Royaume-Uni] ; Ghassan Al-Barghouthy [Royaume-Uni] ; Michael Jackson [Royaume-Uni] ; Lance Smith [Royaume-Uni] ; Bai-Yun Zeng [Royaume-Uni] ; Niall Quinn [Royaume-Uni] ; Peter Jenner [Royaume-Uni]Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa
002858 Alice J. Manson [Royaume-Uni] ; Kirsten Turner [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni]Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: Long-term follow-up study of 64 patients
002916 G. M. Petzinger [États-Unis] ; M. Quik [États-Unis] ; E. Ivashina [États-Unis] ; M. W. Jakowec [États-Unis] ; M. Jakubiak [États-Unis] ; D. Di Monte [États-Unis] ; J. W. Langston [États-Unis]Reliability and validity of a new global dyskinesia rating scale in the MPTP-lesioned non-human primate
002952 Susan H. Fox [Royaume-Uni] ; Brian Henry [Royaume-Uni] ; Micheal P. Hill [Royaume-Uni] ; David Peggs [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni]Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct : Evidence from the effects of the Alpha2 adrenoceptor antagonist idazoxan
002958 Paul Krack [France, Allemagne] ; Rajeev Kumar [États-Unis] ; Claire Ardouin [France] ; Patricia Limousin Dowsey [Royaume-Uni] ; John M. Mcvicker [France, États-Unis] ; Alim-Louis Benabid [France] ; Pierre Pollak [France]Mirthful laughter induced by subthalamic nucleus stimulation
002973 Paolo Del Dotto [Italie] ; Nicola Pavese [Italie] ; Gianna Gambaccini [Italie] ; Silvia Bernardini [Italie] ; Leonard Verhagen Metman [États-Unis] ; Thomas N. Chase [États-Unis] ; Ubaldo Bonuccelli [Italie]Intravenous amantadine improves levadopa-induced dyskinesias: An acute double-blind placebo-controlled study
002980 Olivier Rascol [France] ; I. Arnulf [France] ; H. Peyro-Saint Paul [France] ; C. Brefel-Courbon [France] ; M. Vidailhet [France] ; C. Thalamas [France] ; A. M. Bonnet [France] ; S. Descombes [France] ; B. Bejjani [France] ; N. Fabre [France] ; J. L. Montastruc [France] ; Yves Agid [France]Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease
002997 J. Eric Ahlskog [États-Unis] ; Manfred D. Muenter [États-Unis]Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature
002A02 T. Perniola [Italie] ; L. Margari [Italie] ; M. G. De Iaco [Italie] ; A. Presicci [Italie] ; P. Ventura [Italie] ; E. Ferrannini [Italie] ; G. Illiceto [Italie]Familial paroxysmal exercise-induced dyskinesia, epilepsy, and mental retardation in a family with autosomal dominant inheritance
002A17 Y. R. Wu [Taïwan] ; R. Levy [Canada] ; P. Ashby [Canada] ; R. R. Tasker [Canada] ; J. O. Dostrovsky [Canada]Does stimulation of the GPi control dyskinesia by activating inhibitory axons?
002A60 Eleni C. Maratos [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Ronald K. B. Pearce [Royaume-Uni] ; Peter Jenner [Royaume-Uni]Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus)
002A67 J. I. Hoff [Pays-Bas] ; A. A. V. D. Plas [Pays-Bas] ; E. A. H. Wagemans [Pays-Bas] ; J. J. Van Hilten [Pays-Bas]Accelerometric assessment of levodopa-induced dyskinesias in Parkinson's disease
002A96 Hasmet A. Hanagasi [Turquie] ; Gülüstü Kaptanoglu [Turquie] ; Hüseyin A. Sahin [Turquie] ; Murat Emre [Turquie]The use of NMDA antagonist memantine in drug-resistant dyskinesias resulting from L-dopa
002B26 D. A. Di Monte [États-Unis] ; A. Mccormack [États-Unis, Suède] ; G. Petzinger [États-Unis] ; A. M. Janson [États-Unis, Suède] ; M. Quik [États-Unis] ; W. J. Langston [États-Unis]Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model
002B75 Lucia Angelini [Italie] ; Nardo Nardocci [Italie] ; Margherita Estienne [Italie] ; Chiara Conti [Italie] ; Ivano Dones [Italie] ; Giovanni Broggi [Italie]Life-threatening dystonia-dyskinesias in a child : Successful treatment with bilateral pallidal stimulation
002B76 S. Frucht [États-Unis] ; S. Fahn [États-Unis] ; S. Chin [États-Unis] ; V. Dhawan [États-Unis] ; D. Eidelberg [États-Unis]Levodopa-induced dyskinesias in autopsy-proven cortical-basal ganglionic degeneration
002B94 A. J. Manson [Royaume-Uni] ; E. Iakovidou [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni]Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's disease
002C23 N. L. W. Keijsers [Pays-Bas] ; M. W. I. M. Horstink [Pays-Bas] ; J. J. Van Hilten [Pays-Bas] ; J. I. Hoff [Pays-Bas] ; C. C. A. M. Gielen [Pays-Bas]Detection and assessment of the severity of levodopa-induced dyskinesia in patients with Parkinson's disease by neural networks
002C52 E. Luginger [Autriche] ; G. K. Wenning [Autriche] ; S. Bosch [Autriche] ; Werner Poewe [Autriche]Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's Disease
002C57 Werner Poewe [Autriche] ; Gregor K. Wenning [Autriche]Apomorphine : An underutilized therapy for Parkinson's disease
002C84 Dyskinesias
002C88 F. Durif [France] ; M. Vidailhet [France] ; B. Debilly [France] ; Yves Agid [France]Worsening of levodopa-induced dyskinesias by motor and mental tasks
002C99 F. Cardoso [Brésil] ; R. Faleiro [Brésil]Tourette syndrome : Another cause of movement disorder of the ear
002D01 B. Henry [Royaume-Uni] ; S. H. Fox [Royaume-Uni] ; D. Peggs [Royaume-Uni] ; A. R. Crossman [Royaume-Uni] ; J. M. Brotchie [Royaume-Uni]The α2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-Parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease
002D03 M. Vidailhet [France] ; A. M. Bonnet [France] ; R. Marconi [France] ; F. Durif [France] ; Yves Agid [France]The phenomenology of L-dopa-induced dyskinesias in Parkinson's disease
002D18 MYUNG SIK LEE [Corée du Sud] ; YOUNG DUK KIM [Corée du Sud] ; WON CHAN KIM [Corée du Sud] ; CHUL HYOUNGL YOO [Corée du Sud]Slow rhythmic dyskinesia of the shoulder : One idiopathic and two symptomatic cases
002D19 G. M. Wali [Inde]Shoulder girdle dyskinesia following local surgery
002D20 G. M. Wali [Inde]Shoulder girdle dyskinesia associated with a thalamic infarct
002D33 C. G. Goetz [États-Unis]Rating scales for dyskinesias in Parkinson's disease
002D35 J. M. Brotchie [Royaume-Uni] ; S. H. Fox [Royaume-Uni]Quantitative assessment of dyskinesias in subhuman primates
002D36 P. R. Burkhard [États-Unis] ; H. Shale [États-Unis] ; J. W. Langston [États-Unis] ; J. W. Tetrud [États-Unis]Quantification of dyskinesia in Parkinson's disease : Validation of a novel instrumental method
002D54 P. J. Bedard [Canada] ; P. J. Blanchet [Canada] ; D. Levesque [Canada] ; J.-J. Soghomonian [Canada] ; R. Grondin [Canada] ; M. Morissette [Canada] ; M. Goulet [Canada] ; F. Calon [Canada] ; P. Falardeau [Canada] ; B. Gomez-Mancilla [Canada] ; J.-P. Doucet [Canada] ; G. S. Robertson [Canada] ; T. Dipaolo [Canada]Pathophysiology of L-Dopa-induced dyskinesias
002D56 S. Frucht [États-Unis] ; S. Fahn [États-Unis]Paroxysmal kinesigenic dyskinesia in infancy
002D58 M. G. Cerosimo [Argentine] ; F. Micheli [Argentine]Paroxysmal dyskinesia and gonadal sex hormones
002D72 Pierre Pollak [France]Neurosurgical treatment of dyskinesias : Pathophysiological consideration
002D77 S. Nagamitsu [Japon] ; T. Matsuishi [Japon] ; K. Hashimoto [Japon] ; Y. Yamashita [Japon] ; M. Aihara [Japon] ; K. Shimizu [Japon] ; M. Mizuguchi [Japon] ; H. Iwamoto [Japon] ; S. Saitoh [Japon] ; Y. Hirano [Japon] ; H. Kato [Japon] ; Y. Fukuyama [Japon] ; M. Shimada [Japon]Multicenter study of paroxysmal dyskinesias in Japan : Clinical and pedigree analysis
002D81 Joseph Jankovic [États-Unis] ; L. Ben-Arie [États-Unis] ; K. Schwartz [États-Unis] ; KIM CHEN [États-Unis] ; M. Khan [États-Unis] ; E. C. Lai [États-Unis] ; J. K. Krauss [États-Unis] ; R. Grossman [États-Unis]Movement and reaction times and fine coordination tasks following pallidotomy
002D86 N. Giladi [Israël] ; H. Shabtai [Israël]Melatonin-induced withdrawal emergent dyskinesia and akathisia
002D93 N. Giladi [Israël] ; E. Melamed [Israël]Levodopa therapy can ameliorate tetrabenazine-induced parkinsonism
002D97 R. K. B. Pearce [Royaume-Uni]L-dopa and dyskinesias in normal monkeys
002E19 K. A. Reardon [Australie] ; M. Shiff [Australie] ; P. A. Kempster [Australie]Evolution of motor fluctuations in Parkinson's disease : A longitudinal study over 6 years
002E30 P. Damier [France] ; C. Jaillon [France] ; I. Clavier [France] ; I. Arnulf [France] ; A.-M. Bonnet [France] ; B.-P. Bejjani [France] ; Yves Agid [France]Dyskinesias assessment in phase II studies
002E31 P. Brown [Royaume-Uni] ; A. Manson [Royaume-Uni]Dyskinesias assessment and ambulatory devices
002E32 H. Widner [Suède] ; G.-L. Defer [France]Dyskinesias assessment : From CAPIT to CAPSIT
002E48 P. Hagell [Suède] ; H. Widner [Suède]Clinical rating of dyskinesias in Parkinson's disease : Use and reliability of a new rating scale
002E77 J. I. Hoff [Pays-Bas] ; B. J. Van Hilten [Pays-Bas] ; R. A. C. Roos [Pays-Bas]A review of the assessment of dyskinesias
002E96 F. Ovsiew [États-Unis] ; K. J. Meador [États-Unis] ; K. Sethi [États-Unis]Verapamil for severe hyperkinetic movement disorders
002F15 N. Syed [États-Unis] ; J. Murphy [États-Unis] ; T. Jr Zimmerman [États-Unis] ; M. H. Mark [États-Unis] ; J. I. Sage [États-Unis]Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease
002F16 D. J. Burn [Royaume-Uni] ; A. Coulthard [Royaume-Uni] ; S. Connolly [Royaume-Uni] ; N. E. F. Cartlidge [Royaume-Uni]Tardive diaphragmatic flutter
002F36 MEE OHK KIM [Corée du Sud] ; J.-H. Im [Corée du Sud] ; CHOONG GON CHOI [Corée du Sud] ; MYOUNG CHONG LEE [Corée du Sud]Proton MR spectroscopic findings in paroxysmal kinesigenic dyskinesia
002F53 L. S. Iv Dure [États-Unis] ; H. G. MussellParoxysmal dyskinesia in a patient with pseudohypoparathyroidism
002F57 E. J. Skalabrin [États-Unis] ; E. R. Jr Laws [États-Unis] ; J. P. Jr Bennett [États-Unis]Pallidotomy improves motor responses and widens the levodopa therapeutic window in Parkinson's disease
002F89 P. Krack [France] ; Pierre Pollak [France] ; P. Limousin [France] ; D. Hoffmann [France] ; A. Benazzouz [France] ; Alim-Louis Benabid [France]Inhibition of levodopa effects by internal pallidal stimulation
002F99 D.-J. Yen [Taïwan] ; D.-E. Shan [Taïwan] ; S.-R. Lu [Taïwan]Hyperthyroidism presenting as recurrent short paroxysmal kinesigenic dyskinesia
003044 R. K. B. Pearce [Royaume-Uni] ; T. Banerji ; P. Jenner ; C. D. MarsdenDe novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset
003052 P. A. Lewitt [États-Unis]Conjugate eye deviations as dyskinesias induced by levodopa in Parkinson's disease
003053 M. Merello [Argentine] ; A. Cammarota [Argentine] ; M. I. Nouzeilles [Argentine] ; O. Betti [Argentine] ; R. Leiguarda [Argentine]Confirmation of the antidyskinetic effect of posteroventral pallidotomy by means of an intraoperative apomorphine test
003085 P. J. Blanchet [États-Unis] ; S. Konitsiotis [États-Unis] ; T. N. Chase [États-Unis]Amantadine reduces levodopa-induced dyskinesias in Parkinsonian monkeys
003088 J. M. Brotchie [Royaume-Uni]Adjuncts to dopamine replacement : A pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease
003094 L. V. Metman [États-Unis] ; P. J. Blanchet [États-Unis] ; P. Van Den Munckhof [États-Unis] ; P. Del Dotto [États-Unis] ; R. Natte [États-Unis] ; T. N. Chase [États-Unis]A trial of dextromethorphan in Parkinsonian patients with motor response complications
003140 A. Meyer-Lindenberg [Allemagne] ; B. Krausnick [Allemagne]Tardive dyskinesia in a neuroleptic-naive patient with bipolar-I disorder : Persistent exacerbation after lithium intoxication
003160 K. A. Gwinn [États-Unis] ; J. N. Caviness [États-Unis]Risperidone-induced tardive dyskinesia and parkinsonism
003177 MYUNG SIK LEE [Corée du Sud] ; CHUL HYOUNG LYOO [Corée du Sud] ; WON CHAN KIM [Corée du Sud] ; HO JEONG KANG [Corée du Sud]Periodic bursts of rhythmic dyskinesia associated with spinal anesthesia
003379 P. J. Blanchet [Canada] ; R. Grondin ; P. J. BedardDyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates
003416 P. J. Blanchet [États-Unis] ; L. V. Metman [États-Unis] ; M. M. Mouradian [États-Unis] ; T. N. Chase [États-Unis]Acute pharmacologic blockade of dyskinesias in Parkinson's disease
003478 J. W. Mink [États-Unis] ; J. J. NeilMasturbation mimicking paroxysmal dystonia or dyskinesia in a young girl
003512 R. K. B. Pearce [Royaume-Uni] ; M. Jackson [Royaume-Uni] ; L. Smith [Royaume-Uni] ; P. Jenner ; C. D. MarsdenChronic L-DOPA administration induces dyskinesias in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix jacchus)
003554 C. G. Goetz [États-Unis] ; G. T. Stebbins ; H. M. Shale ; A. E. Lang ; D. A. Chernik ; T. A. Xhmura ; J. E. Ahlskog ; E. E. DorflingerUtility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intrarater reliability assessment
003556 J. N. Caviness [Royaume-Uni] ; A. Gabellini ; C. S. Kneebone ; P. D. Thompson ; Andrew Lees (neurologue) [Royaume-Uni] ; C. D. MarsdenUnusual focal dyskinesias: the ears, the shoulders, the back, and the abdomen
003570 J. P. Jr Bennett [États-Unis] ; E. R. Landow ; S. Dietrich ; L. A. SchuhSuppression of dyskinesias in advanced Parkinson's disease: moderate daily clozapine doses provide long-term dyskinesia reduction
003576 T. R. Jr Zimmerman [États-Unis] ; J. I. Sage ; A. E. Lang ; M. H. MarkSevere evening dyskinesias in advanced Parkinson's disease: clinical description, relation to plasma levodopa, and treatment
003589 A. P. Sempere [Espagne] ; J. Duarte [Espagne] ; J. M. Palomares ; F. Coria ; L. E. ClaveriaParkinsonism and tardive dyskinesia after chronic use of clebopride
003602 R. Marconi [France] ; D. Lefebvre-Caparros ; A.-M. Bonnet [France] ; M. Vidailhet [France] ; B. Dubois [France] ; Yves Agid [France]Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology
003627 M. Kyllerman [Suède] ; O. H. Skjeldal ; M. Lundberg ; I. Holme ; E. Jellum ; U. Von Döbeln ; A. Fossen ; G. CarlssonDystonia and dyskinesia in glutaric aciduria type I: clinical heterogeneity and therapeutic considerations
003669 A. J. Stoessl [Canada] ; E. Polanski ; H. FrydryszakThe opiate antagonist naloxone suppresses a rodent model of tardive dyskinesia
003692 R. E. A. Van Emmerik [Pays-Bas] ; R. L. Sprague ; K. M. NewellQuantification of postural sway patterns in tardive dyskinesia
003697 M. B. Harrison [États-Unis] ; G. R. Lyons ; E. R. LandowPhenytoin and dyskinesias : a report of two cases and review of the literature
003698 F. Javier Jimenez-Jimenez [Espagne] ; F. Cabrera-Valdivia ; L. Ayuso-Peralta ; J. Tejeiro ; A. Vaquero ; E. Garcia-AlbeaPersistent parkinsonism and tardive dyskinesia induced by clebopride
003699 P. A. Lewitt [États-Unis] ; A. Walters ; W. Hening ; D. MchalePersistent movement disorders induced by buspirone
003774 M. Stacy [États-Unis] ; Joseph Jankovic [États-Unis]Tardive tremor
003775 P. C. G. Nijssen [Pays-Bas] ; C. C. TijssenStimulus-sensitive paroxysmal dyskinesias associated with a thalamic infarct
003779 I. J. Mitchell [Royaume-Uni] ; A. R. Crossman ; U. Liminga ; P. Andren ; L. M. GunneRegional changes in 2-deoxyglucose uptake associated with neuroleptic-induced tardive dyskinesia in the cebus monkey
003800 J.-F. De Saint Victor [France] ; C.-L. GervasonLevopoda-induced diphasic dyskinesias improved by subcutaneous apomorphine
003823 C. E. Clarke [Royaume-Uni] ; J. M. Bamford ; A. HouseDyskinesia in Creutzfeldt-Jakob disease precipitated by antidepressant therapy
003852 M. J. Steiger ; N. P. Quinn ; C. D. MarsdenSickness due to levodopa-induced neck dyskinesias in Parkinson's disease
003922 N. M. J. Rupniak ; S. J. Tye ; M. J. Steventon ; S. Boyce ; S. D. IversenSpontaneous orofacial dyskinesias in a captive cynomolgus monkey : implications for tardive dyskinesia
003926 R. Ranawaya ; D. Riley ; A. LangPsychogenic dyskinesias in patients with organic movement disorders
003930 K. D. Sethi ; A. Hitri ; B. I. DiamondPhenytoin potentiation of neuroleptic-induced dyskinesias
003939 M. A. Menza ; J. Sage ; E. Marshall ; R. Cody ; R. DuvoisinMood changes and on-off phenomena in Parkinson's disease
003943 S. Boyce ; C. E. Clarke ; R. Luquin ; D. Peggs ; R. G. Robertson ; I. J. Mitchell ; M. A. Sambrook ; A. R. CrossmanInduction of chorea and dystonia in parkinsonian primates
003957 G. Iliceto ; P. D. Thompson ; B. L. Day ; J. C. Rothwell ; Andrew Lees (neurologue) [Royaume-Uni] ; C. D. MarsdenDiaphragmatic flutter, the moving umbilicus syndrome and "Belly dancer's" dyskinesia
003972 A. R. CrossmanA hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment
003977 W. C. Koller ; N. M. BiaryVolitional control of involuntary movements
003991 U. Andersson ; J.-E. Haggstrom ; E. D. Levin ; U. Bondesson ; M. Valverius ; L. M. GunneReduced glutamate decarboxylase activity in the subthalamic nucleus in patients with tardive dyskinesia
003993 W. C. Koller ; G. F. Wong ; A. LangPostraumatic movement disorders: a review
003A07 E. Pourcher ; A.-M. Bonnet ; J. Kefalos ; B. Dubois ; Yves Agid [France]Effects of etybenzatropine and diazepam on Levodopa-induced diphasic dyskinesias in Parkinson's disease
003A16 L. E. Adler ; M. Pecevich ; H. NagamotoBereitschaftspotential in tardive dyskinesia
003A77 M. R. Samie ; M. A. Dannenhoffer ; S. RozekLife-threatening tardive dyskinesia caused by metoclopramide

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024